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The ceramide analog, D.theeo-l.phenyl.2.decanoylamino-3.morpholino-l.propanol, inhibits the glucosylation o! cera- 
mide and thus, by virtue of the normal catabolism of the higher glucosphingolipids, leads to a general depletion of 
cellular glucolipids. In a previous study with chronic administration ol this inhibitor in mice, it was iound that the 
kidneys and liver, particularly the former, grew more poorly than the organs of control mice. This study. ~hmvs that the 
inhibitor produces rapid decreases in glucolipid concentration in kidney which are maintained for at least 5 days without 
noticeable harm. The changes were enhanced by inclusion of L-cyclo~rine in the injection .scheme. Cycloserine blocks 
ketosphinganine synthase and thus slows the synthesis of all sphingoliplds. However, sphingomyelin levels did not drop 
significantly in this study. The glucosyltransferase inhibitor also produced a small decrease in kidney ~-D-glucuronid~tse 
and distinct increases in the levels of glucocerebrosidase, galactocerebrosida.se and sphingomyclinase. It also produced a 
small but distinct decrease'in the level of glucosyltransfer',tse, after a delay of a few hours, pogsibly becuase the inhibitor 
was metabolized to a covalentiy inactivating product. Comparison with kidney, liver and brain showed that the kidney 
was more sensitive to the action of the mo~holino inhibitor. 
Introduction 
G|ycosphingolipidoses are inborn errors of metabo- 
lism involving a major deficiency in hydrolase activity. 
In most of these disorders, such as Gaucher, Fabry and 
Tay-Sachs diseases, the inadequate activity results in 
accumulation of the slowly catabolized lipid, evidently 
because direct feedback controls for slowing the synthe- 
sis do not exist, The suggestion has been made [1] that it 
might be possible to alleviate the symptoms of these 
disorders by using an enzyme inhibitor to slow the 
biosynthesis of glucosylceramide (GIcCer), the pre- 
cursor of all the glucosphingolipids, This would allow 
the residual glycosidase activity to match the rate of 
Abbreviations: CMH, ceramide monohexoside (mainly GIcCer); 
CDH, ceramide dihexoside (lactosylceramide or LacCer): CS. L- 
cycloserine; GIcCer, glucosylceramide or glucocerebroside: PDMP, 
threo-l.phenyl.2.dccanoylamino-3-morpholino-l-propanol. 
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synthesis and block the accumulation of the involved 
glucosphingolipids. Only a small reduction in the rate of 
synthesis would be neces~ry, since the rate of gluco- 
sphingolipids accumulation (in all but the infantile forms 
of these disorders) is fairly slow. We have developed an 
inhibitor of GlcCer synthase, D-threo-l.phenyl-2-de- 
canoylamino-3-morpholino-l-propanol (D-PDMP), 
which works in cultured cells at the 5 to 20/tM level to 
lower the levels of GlcCer [2-4]. As the higher gluco- 
sphingolipids undergo catabolism, their levels also de- 
crease. The inhibitor acts in mice to retard or stop the 
growth of several kinds of inoculated tumors [5,61. In 
the mice which had been freed of cancer cells, the 
animals appeared to grow normally after the treatment 
period was halted. 
In tests with normal mice [5], it was found that 10 or 
12 daily injections of D-PDMP led to reductions in liver 
and kidney size, the decrease being more persistent with 
the latter organ (as measured 40 h after halting the 
injections). Mouse kidney is noted for its high rate of 
excretion into urine of glucosphingolipids, as well as the 
involvemen t, of some of these lipids in stage-specific 
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development and sex differences, so it is possible that 
this organ is particularly sensitive to the rate of GlcCer 
synthesis [7]. Moreover. it was found with D-[~H]PDMP 
that the highest concentration and longest persistence of 
the inhibitor appeared in kidney (Shukla, A. and Radin, 
N.S., unpublished data). 
i.-(ycloserine (CS) has been found to block sphingo- 
sin,: synthesis and reduction in brain glycolipid content 
has bccn reported [8]. Its use in Gaucher disease, follow- 
ing the rationale des::ribed above, has also been sug- 
gested [91. 
This paper describes additional effects of injecting 
normal mice with D,I.-PDMP (rather than the D-enanti- 
omcr), with and without CS. Surprisingly rapid changes 
in the levels of the simple glucosphingolipids and 
sphingolipid hydrolases were found. 
spleen. Triton X-100. sodium taurocholate and phos- 
phate-citrate (pH 5.0)[11]. 
Galactocerebrosidase was assayed similarly, with 
NBD-substituted cerebroside [12]. using 0.2 to 0.5 mg of 
tissue. Sphingomyelinase was assayed with 2-hexa- 
deeanoylamino-4-nitrophenylphosphorylcholine in 0.105 
ml containing 1.5 mg of tissue [13] and B-glucuronidase 
was assayed with phenolphthalein monoglucuronate [14], 
using 0.5 mg liver. 1 mg kidney or 5 mg brain per tube. 
Ceramide: UDP-[3Htglucose glucosyltransferase was 
assayed by an improved method [15] which utilizes 
NAD to protect the nucleotide sugar against pyrophos- 
phatase, an ultrasonic incubation bath and a new 
liquid/liquid solvent mixture for isolating the GIcCer 
formed. In the case of liver and brain synthases. A'IP 
was used as the pyrop',aosphatase inhibitor. 
Materials and Methods 
Animals 
Mice of the ICR strain, from Harlan Sprague Daw- 
ley. were obtained at a weight of 20-22 g and kept in 
our animal room until they weighed about 28 g. In most 
experiments, they were then sorted by weight into 
matched subgroups with a computer program which 
produced subgroups of similar mean weights and stan- 
dard distributions [10]. Three subgroups of three each, 
or two subgroups of five each, were assigned at random 
into control or experimental groups. All mice were 
injected i.p. with isotonic saline containing the nonionic 
detergent, Myrj 52 (ICI Americas) at 12 mg/mt. The 
experimental mice also received PDMP in the same 
medium, at 8 mg/ml, with or without added CS. 
~7~emic'als 
1~.1.-. D- and i.-PDMP. HCI were prepared as de- 
scribed [21 and dissolved in Myrj-saline by warming to 
approx. 50 °C. Excess solution was stored in the cold 
and rewarmed as needed, i.-Cycloserine free base and 
most reagents were from Sigma Chemical. Cycloserine 
solutions were made just before use. UDP-D-[6-~H]glu - 
cose was from Amersham. 
E,~-vme assays 
The brain and liver and each pair of kidneys from 
each animal were stored at -70°C,  then homogenized 
ill 9 vols. of water shortly before being assayed. Aliquots 
of each horaogenate were assayed in duplicate; since 
five mice were in each group, the data reported are the 
means of 10 observations. All enzyme assays were 
checked to make sure that the observed activities were 
proportional to tissue weight and length of incubation. 
Glucocerebr~,idase was assayed with the fluorogenic 
substrate, NBD-GIcCer, with 0.1-0.2 mg of tissue in a 
total volume of 0.2 ml containing GicCer from Gaucher 
Lipid assays 
The organs from the five mice in both subgroups 
were weighed immediately after dissection, then stored 
at - 7 0 ° C  until analyzed. They were extracted with 
hexane-isopropyt alcohol [16] and the acidic lipids were 
removed by column chromatography using chloroform/ 
methanol/water (60 : 30 : 8) with Accell resin (a 
quaternary amine from Waters, Millipore Corp.) in the 
acetate form. Alkaline methanolysis in chloroform/ 
methanol/NaOH decomposed the glycerolipids and a 
column of silica gel (Merck silica gel 60) separated the 
lipids into fractions for quantitative determination by 
TLC. 
The ceramide fraction ,.,'as chromatographed on 0.25 
x200×200  mm silica gel plates (E. Merck) with 
hexane/chloroform (1:1), then with chloroform/ 
methanol/acetic acid (91:2: 3): the standards were 2.5 
and 5 v.g of ceramide derived from beef brain sphlngo- 
myelin. The CMH-CDH fraction was chromatographed 
with chloroform/methanol/water (60:10:1, then with 
24:7:1). The GlcCer standard, from Gaucher spleen, 
weighed 2.5 and 5 v.g and the lactosylceramide standard 
weighed 7.5 and 15/.tg. The sphingomyelin fraction was 
chromatographed with chloroform/methanol/water 
(60:35:8); the standards were 4 and 8 t.tg of brain 
sphingomyelin. Each standard and each column frac- 
tion was applied to the plate in duplicate: a total of 13 
samples per plate was applied with a streak applicator 
as 36 ,al streaks. 
The lipid bands were visualized by impregnating the 
plates with a modified charring reagent [17], 100 g of 
CuSO4.SH,.O in cone. H.~POa/water/MeOH (100- 
750-400 ml). As noted by previous v Jlkers [18], kidney 
cerebroside (CMH) is a mixture ol monohexosylcera- 
mides formed from sphingosine, phytosphingosine, non- 
hydroxy fatty acids, 2-hydroxy fatty acids, glucose and 
galactose, and :bus forms several CMH bands. Only the 
fastest pair of TLC bands (long-chain and very-long- 
chain nonhydroxy acids) was quamitated but the de- 
creases produced by PDMP and CS were visibly evident 
in the lower CMH bands too. {This suggests that the 
polar CMH's and less-polar CMH's have similar 
turnover rates.) A similar situation was seen for CDH 
but the mixture was not as complex. 
The lipid bands were quantitated by reflected light 
videodensitometry, using an Apple lie computer fitted 
with a digitizing board and stabilized with two types of 
voltage stabilizers in series. This is an improved ver,£on 
of a oreviously described device [I9], Each (quadrupli- 
cate) reading of a spot took 20-30 s, 
Stwistical analysis 
The data were analyzed by one-way ANOVA and the 
Scheff6 F-test, The differences between control and 
experimental groups significant at the 95,.% level are 
labeled with an asterisk. 
R e s u l t s  
Lipid changes 
In Expt, 1, 28-g mice were divided into three groups, 
each of which consisted of two five-mouse subgroups. 
The kidneys from each subgroup were pooled and ex- 
tracted, Subgroups A1 and A2 were controls, injected 
i.p. only with Myrj in saline, 150 mg/kg. Group B 
received the same injections, including O,L-PDMP (100 
mg/kg). Group C was like B but 40 mg/kg of CS were 
included. 5 h after the injection, the mice were killed 
and assayed for lipid changes (Table i). 
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PDMP was seen to produce a rapid decrease in 
GIcCer, indicating that this lipid has a high turnover 
rate in kidney. Since GicCer is formed by two mecha- 
nisms, ceramide glucosylation and hydrolysis of the 
higher gtucosphingolipids, only the first of which is 
blocked by PDMP, it appears that the synthetic path- 
way must have been blocked rather completely and that 
the GlcCer seen was derived mainly from the second 
process, The lesser percentage decrease in LacCer is to 
be expected since it was still being synthesized from 
residual GlcCer. as well as by hydrolysis of the higher 
glucosphingolipids. While the average rates of :~bsolute 
loss were similar for both glucosphingolipids {2,4 ,ag/g 
per h for CMH and PDMP alone, 2.7 ~g /g  per h for 
CDH), this similarity is coincidental since the rates of 
loss depend on multiple factors - the rate of PDMP 
loss from kidney, the rates of CMH and CDH hydroly- 
sis and synthesis, the rates of excretion into urine and 
the differences in turnover between different gluco- 
sphingolipid subcellular pools. 
Ceramide and sphingomyelin decreased only slightly 
in the mice ,,teated with PDMP alone, but inclusion of 
CS - which slows the synthesis of all sphingolipid., - 
produced a marked decrease in ceramide level and 
augmented the effect of PDMP on LacCer, 
In Expt. 2. an attempt was made to increase and 
prolong the effects. Here there were two injections, 3.5 
h apart and at a higher level, The dosages in the first 
injection were 125 mg/kg D,t,-FDMP and 50 mg/kg 
CS: in the second injection the PDMP dose was in- 
creased to 150 mg/kg. All mice were killed 3.5 h after 
TABLE I 
Lipid change.s #! kidneys 5 h after a single o!jettion #f o.t.-PDMP ( t1~) mg/ kg) or PDMP ÷ I-,ydoserme f40 mg/kg) 
Data are the means of the dePsitometric measurements of lhree TLC bands. ]-he three hands were obtained from the lipids extracted from 10 
kidneys from five mice. The pairs of lines (such as A1 and A2) were obtained from two ~el~ of five mice each: Ihus the cafculated means and S.D.'s 
are the result of measuring six TLC bands. Note the close agreement helwecn each pair of five mice: Ihis shows the effectiven,~ss o{ lhe animal 
matching prc, c:ss and the lipid technology. 
Treatment Ceramide ('M H t'DH Sphingomyelin 
(pg/g) (~tg/g) ($tg/g) (rag/g) 
Controls 
AI 104,2 32.1 90.9 2.77 
A2 106,7 35.5 o~ .g 3.05 
Mean + S.D. 105.4+ 1.8 33.~_+ 1,9 ql.4± l.O 2.91 _+0.16 
PDMP 
BI 93.8 20,7 79.5 2.62 
B2 99.0 22.9 75.9 2.82 
Mean + S.D. 96.4_+ 3,0 21.,~_+ 1.3 77,7± 2.2 2.72+_0.12 
(~ change) ( - 9~) * ( - 35~) * l - 15c; ) * ( - 7~'~ ) 
PDMP+CS 
CI 81.1 22.1 702 2.84 
C2 85.8 243 63,4 2.69 
Mean + S.D. 83.5 ___ 2.7 23.4 _+ 1.4 66,7 _.* 3.8 2.76 q- 0.09 
(~ change) ( - 2 1 %  * ( - 31q:) * ( - 2 7 ~  ) * ( - S r ~ )  
* Si~nifi~;~*ntly differcn! from the controls. 
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TABLE II 
Lipid change.~ u; kidneys 7 h after the first of two rejections o] o, I..PDMP or PDMP + t-o'closerine or o,closerine alnne 
Data arc the means of the densitometric measurements of three TLC bands, The three bands were obtained from the lipids extracted from I0 
kidneys from five mice. Groups 1 and 2 are subgroups of five mice each. as in Table I. See Results for details of injections, 
Treatment Ceramide CMH CDH Sphingomyelin 
I ~g/g) (~tg/g) (t~g/g) (rag/g) 
Controls 
AI 107.t 34.1 85.2 2.57 
A2 108.7 33,8 88.3 2,76 
Mean + S.D. 107.9 + 1,3 33.9 +_._ 0,3 86.8 _+ 1.9 2.66 _ 0_14 
PDMP 
B1 102.5 24,2 71.5 2.91 
112 95.2 23.6 70,8 2.70 
Mean .4: SD. 98.8+4.1 23.9+0.4 71.1 +1,1 2.81 m0.14 
1% change) ( -8%) * (-30%) * ( -  18%)" ( +5%1 
PDMP + CS 
C] 54_8 19.2 56.6 2.52 
C2 55.7 19.5 56.1 2.57 
Mean + S.D. 55.2 _ 0,7 19,4 5:0.3 56.4 _+ 0.7 2.54 + 0.10 
(~, chan~,c) ( - 49%) * ( -43%) * ( - 35%) * ( - 5~) 
Cycloserinc 
D1 55.0 32.2 80.2 2.49 
D2 56.1 32.4 76,9 2.51 
Mean _+ S.D. 55,5 _+0.9 323 +0.3 78,5 + 2.1 2.50 ± 0,10 
(% change) (-49%) * ( -5%)  ( -9%)  * ( -6%)  
* Significantly different from the controls, 
TABLE i11 
Lipid changes in kidneys of 25.5 g mice, injected twice a day, at 9:O0 a,m. and 5:O0 p.m., for 4 days. After a final injection in the morning of the fifth 
din', the mice were killed 6.5 h later. The dosages were changed each day as follows: o,I.-PDMP was 150, 120, 100, 90 and 90 mg /kg  each day; CS was 
.~0, 40, 3?, 30 and 30 mg/kg  each day 
Data are the means of the densitometric measurements of three TLC bands as described in Table I. 
Treatment Ceramide CMH CDH Sphingomyetin 
(#g/g) (ttg/g) (aB/8) (m8/8) 
Controls 
At lO8.3 32.4 81.6 2.70 
A2 102.0 33.2 85.4 2.76 
Mean + S.D, 10f6 +_ 3,6 32.8 + 0.5 83.5 + 2,3 2.73 + 0.08 
PDMP 
BI 79,9 22.7 72,6 2.89 
B2 82.4 22.7 76.4 2.80 
Mean + S.D. 81.3 +_ 1,6 22.7 4" 0.3 74,5 5:2,3 2.85 ± 0.10 
t~ change) (-23%) * (-31%) * ( - i1%) * (+4%) 
PDMP+CS 
C1 58,8 15.4 57,2 2.85 
C2 52.4 17.5 54.5 2.88 
Mean _+ S.D. 55.6 + 3.6 16.4 + 1,2 55.9 5:1.6 2,86 5:0.09 
ill change) ( -  47%) * ( -  50%) * ( - 33%) * ( + 5%) 
Cycloserinc 
D! 62.0 31.5 81,2 2.59 
D2 60.9 33.0 83.2 2.61 
Mean + S.D. 61.4 _+ 1.0 323 4-1.0 82.2 5:1.4 2.60 5:0.04 
(g: changet ( - 4270) * ( - 2%) ( - 2%) ( - 5%) 
* Significantly different from the controls. 
the last injection. An additional group, given CS ~- Myrj, 
was included in this experiment. 
The results were similar to those of Expt. 1 and it 
was now apparcnt that the loss of ceramide was prim- 
arily due to the ability of CS to block sphingosine 
synthesis (Table II). This time, with the longer exposure 
to higher doses of inhibitors, LacCer decreased even 
more. The effect of CS on the ceramide level was a!so 
disti,lctly greater. 
While the kidney weights in Expt. 1 had not de- 
creased significantly, here group C had kidneys that 
were 14% smaller and group D kidneys were 10% smaller 
( e < 0.05, n = 10). 
Similar decreases in CMH and synergistic action 
were seen in liver after subcutaneous injection of D- 
PDMP and CS as the stearate salts together with Myrj 
(unpublished data). In one such experiment, the con- 
centration of total lipids in liver also decreased (10% 
with o-PDMP, 217~ with PDMP + CS, 23% with CS 
alone). The opposite effect on total liver lipids was 
produced by elevating the organ's GIcCer level, espe- 
cially when the GIcCer was protected against gluco- 
sidase action by conduritol B epoxide [201. 
In Expt. 3, an attempt was made to see whether the 
lipid changes could be maintained over a period of time 
or whether some adaptive metabolic normalization oc- 
curred when the two inhibitors were injected twice a 
day. At the dose levels used (Table llb, the treated mice 
lost weight and the dosages were accordingly reduced 
each day. By the end of the fifth day, the average 
decreases in body weight were 18% in the PDMP group 
(B), 22~ in the PDMP-CS group (C) and 14% in the CS 
group (D), significant differences when compared with 
the control mice. The kidney weights decreased pro- 
portionately. 
The changes in lipid concentrations were similar to 
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those seen in Table Ii, except for the enhanced lowering 
effect of PDMP on ceramide. Evidently. the enzyme 
blockages and their sequelae could be maintained over a 
longer period of time, making the therapeutic use of the 
two inhibitors even more promising. 
Expt. 4 was run to determine whether a lower dose of 
PDMP could be used and whether the L-enantiomer 
might interfere with the action of the D-enantiomer (the 
actual inhibitor of GlcCer synthase). The protocol was 
similar to that of Expt. 2 (a total of 7 h of exposure to 
PDMP) but three three-mouse subgroups were used 
instead of two five-mouse subgroups to produce the 
reported values. It was evident that reducing the dosage 
of I),L-PDMP reduced the magnitude of the loss in 
GtcCer and lactosylceramide (Table IV). In this experi- 
ment, the change in ceramide level was not as large as 
before, ts-PDMP, at 80 rag/ks, produced the equivalent 
effect of 160 mg/kg of the racemic mixture. L-PDMP 
produced some decreases but the changes were not 
statistically significant. We conclude that the use of the 
(cheaper) D,L-mixture gives results that are similar ~:o 
those of D-PDMP in short-term experiments. 
E n - v m e  changes 
When GlcCer levels were increased in mice by block- 
ing glucosidase with conduritol B epoxide, the levels of 
several enzymes changed. B-Glucuronidase decreased in 
mouse liver but increased in brain [14}. Other enzyme 
changes have been reported in brain [21] and, with a 
different glucosidase inhibitor, in cuhured neuronal ceils 
[22]. Marked elevations of certain apparently-unrelated 
enzymes in spleen and plasma occur it~ Gaucher pa- 
tients 123]. It therefore seemed appropriate to seek 
enzyme changes in mice whose GIcCer level had been 
lowered, especi~.lly enzymes involving sphingolipids. 
Expt. 5 was run with the protocol used in Expt. 2, 
TABLE IV 
Lipid changes in kidneys 7 h after the first o/two injvctwns of t~.t-, o- or t-PDMP 
Data are the means of the densitometric measurements:t S.D. of six Tt.C bar.ds derived from three subgroups of three mice each, analy:,ed in 
dapticale. 
Treatment Ceramide CM H CDH Sphingomydin 
(~g/g) ~g/g) (~g/g) (rag/g) 
Controls 112 + 4 37.1 _+ (}.7 97 + 4 2.85 +_ 0.13 
D,L-PDMP 160 mg/kg 108 + 5 26.8 +_ 1,2 84 ± 5 2.98 + 0.16 
(% change) ( - 4 ~ )  ( - 2 8 ~ ) "  ( - 13%)" ( + 5~) 
D.L.PDM P 80 mg/kg t I I ± 3 30.3 + 0.5 q9 _+ 6 3.03 _+ 0,19 
1~ change) {- 1%) t - 18%)" ( + 2'~) (+ 6'~) 
o-PDMP 80 rag/ks 1225:4 27.5 _+ 0.8 95 ± 3 3.05 +_ 0.20 
[% change) (+9,~) * ( -  26~1" I + 2%) ( ~- 7'g) 
L-PDM P 80 mg/kg 104 + 4 36.4 4-1.5 90 _+ 4 2.73 _+ o.18 
[% change) ( - 7%1 ( - 2~ ) ( - 7wo) ( - 5~ 
* Significantly different from control mice. 
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but only five mice were used per group and the pooled 
kidneys of each mouse were assayed for three sphingo- 
lipid hydrolases and glucuronidase. Cycloserine pro- 
duccd no significant changes (Table V) but PDMP 
produced distinct increases in the sphingolipid hydro- 
lases and a decrease in glucuronidase. 
Expt. 6 was run to see if PDMP exerted any effect on 
the level of GlcCer synthase (it is not uncommon for an 
organism to respond to an inhibitor by synthesizing 
additional enzyme molecules). Five groups of mice (five 
mice per group, average wt. 36.1 + 1.2 g) were injected 
once with D-PDMP, at 80 mg/kg i.p. and killed 1/3,  1, 
3, 8 or 24 h after the injection. Three organs from each 
mouse were separately assayed for glucosyltransferase 
activity. Five control mice received only the Myrj 52 
injection. For the early time points, it was necessary to 
use relatively small portions of tissue to dilute out the 
PDMP still in the tissue. Thus, the observed activities 
reflect the actual amount of enzyme activity in the 
tissues rather than their degree of inhibition in vivo. 
Tests with animals injected with Myrj alone showed 
that it had no effect. 
No significant change was seen in the transferase 
level during the first hour after PDMP injection (Fig. 
I ); by 4 and 8 h, kidney showed significant decreases in 
enzyme level but this normalized by 24 h. Liver also 
showed a significant loss of enzyme by 3 h and also 
normalized. Brain did not show any significant dif- 
ferences. A study of D-[1-'~H]PDMP metabolism 
(Shukla. A. and Radin, N,S, unpublished data) has 
revealed that the inhibitor is rapidly metabolized and 
excreted so one might expect to see no inductive effects, 
but a small proportion of the compound was converted 
to labeled water. Since the label was on carbon-1 of the 
inhibitor (the hydroxylic carbon), it is likely that it was 
converted to water by oxidation to the ketonic analog. 
The ketone (2 -decanoy lamino-3-morpho l inopro-  
piophenone) is an inactivating inhibitor of the gluco- 
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Fig. 1. Glucosyltransferase activity of tissues from five mice (per time 
point) injected once with I)-PDMP. 80 me/ks and 120 me/ks of the 
detergent. Myrj 52. The tissue from each animal was homogenized 
(both kidneys were pooled) and portions assayed for activity, using 
oetanoyl sphingosine as glucose acceptor. The error bars show the 
S.D. The zero time activity is based on mice injected only with Myrj 
in saline and killed 3 h later. * Significantly different from the 
controls at 95%. 
that the effective enzyme activity in vivo is lowered by 
PDMP in two ways, by direct contact and resultant 
inhibition and by chemical inactivation of some of the 
enzyme. The recovery with time to normal transferase 
levels (Fig. 1) is probably due to resynthesis of new 
enzyme molecules. In a previous study in mice with a 
single injection of ketonic form of PDMP [241, the 
glucosyltransferase level in liver rebounded to 20% above 
normal within 24 h, 
Expt. 7, run as in Expt. 6 with a 7-h exposure to 
isomeric forms of PDMP, produced changes in GlcCer 
glucosyhransferase similar to those seen in Fig. 1. L, 
PDMP had no effect and the brain enzyme showed no 
changes with any of the drugs used (unpublished data), 
From th:  latter observation, the observed decreases in 
kidney enzyme level (Expt, 6), and the finding that 
D-PDMP readily penetrates the brain (Shukla, A. and 
TABI_t- V 
E,r~rme ('hange.~ m ktdm:vs of 28.3 g mice 7 h after rite first of two injections of D.t.-PDMP or PDMP + t..tydo.wrine or (y('loserine ahme 
l)o.lll ar~: the mean.', and S.D.'s obtained from duplicate assays of the two kidneys homogenized from each of the five mice per group. The enzyme 
aclivilies tire in nrnol/h per mg lissue. Protocol described in text. 
"treatment Glucosidase Ga]actosidase Sphingomyclinase Olucuronldase 
Controls 23.9 + 0,8 l 1.8 ± 0.5 7.31 + 0.97 12.3 + 0.3 
PDMP 29,8 + 2,3 15.8+_ 1,3 9.70_+ t.2 10.9_+0.5 
(q ch;,nge) ( + 2UI ) * ( + 34~) " ( + 33e~ ) * ( - I I ~  ) * 
PI)M P + CS 28.9 +_ 03 16.4 _+ 0.'4 10.24 +_ 1.6 10.9 _+ 0.4 
It/ change) ( + 21 ri ) * ( + 38~ ) " ( * 40e~ ) * ( - 11 ~ ) * 
('vclo~¢rinc 24.4 + l.l 12.7 + 0.8 7.22 _+ 0.91 12.4 ~+ 0.4 
(~ change) ( + 2~/) t + 8~'i ) ( - l~l ( + 1 ~) 
* Significantly different from control mice. 
Rodin. N.S., unpublished data), it appears likely that 
the brain does not oxidize PDMP to the ketone. Liver 
and kidney both showed decreased levels of gluco- 
syltransferase specific activ'.ty when 160 mg/kg of L~.I.- 
PDMP or g0 mg/kg of r~-PDMP was injec!ed but the 
lower dose, 80 mg/kg of D,t,-PDMP. produced only a 
small, statistically nonsignificant decrease. 
Glucocerebro~idase, as in Expt, 5, was significantly 
increased in kidney but not in liver or brain. Unex- 
pectedly, the increase appeared with all mice injected 
with PDMP, including the 80 mg/kg doses of o,t.- and 
L-PDMP. The same was found for sphingomyelinase 
and galactt~sy!ceramide/~-galactosidase and, as before, 
the increases were larger than for glucosida,se. B-o- 
glucuronidase was slightly but significantly decreased 
only in kidneys of mice injected with 160 mg/kg of 
t).L-PDMP. Thus. it appears again that kidney is some- 
what more sensitive to PDMP than brain or liver. A 
direct effect of t),t,-PDMP on these enzymes was ruled 
out by adding ! to 100 ~tM PDMP to the homogenates: 
no effect was seen (except for GIcCer synthase). 
Discussion 
Our finding that CS and PDMP work synergistically 
to lower GlcCer levels suggests that a mixture of the 
two would be even more useful in the proposed applica- 
tions listed in the Introduction. Both inhibitors enter 
the brain (Shukla, A. and Rodin, N.S., unpublished data 
and Ref. 9) so they shculd b~: cffcc~iv,: in preventing the 
brain deterioration seen in some sphingolipidosis pa- 
tients. CS also inhibits a variety of pyridoxal-dependent 
enzymes to some extent, which might limit its usefulness 
for long-term therapy. The enantiomer of CS, t)- 
cycloserine, is used clinically as an antibiotic to only a 
minor degree, possibly because of this effect on pyri- 
doxal enzymes. L-CS has been used in chronic doses in 
rabbits [25] and in mice [9] to slow sphingosine synthe- 
sis. 
While the enantiomer in o,t,-PDMP active against 
GtcCer synthase is the o-isomer, t-PDMP has been 
found to lower glucosphingolipid levels in cultured cells, 
although it is not as dose.effective as the o.isomer [41. 
Since our findings do not reveal any serious harmful 
effects of the racemic mixture, it is thus reasonable to 
use the cheaper mixture in viva. In fact, the t.-enanti- 
omer appears to exert its glucosphing, otipids-lowering 
effect by slowing the synthesis of ceramide (compare 
the data in Table IV). Although t.-PDMP did not pro- 
duce a significant decrease in that experiment, the de- 
crease was consistent with the decrease seen in the 
sphingomydin level. In this experiment, conversely, o- 
PDMP produced a significant rise in ceramide level and 
a nonsignificant rise in sphingomyelin. Similarly, D- 
PDMP has caused an increased amount of radioactivity 
(from labeled precursorl in the ceramide of cultured 
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cells [4.261, Thus. the i.-cnantiomer in the racemic mix- 
ture may counteract the tendency of o-PDMP to cause 
an accumulation of ceramide and stimulate sphlngo- 
myelin formation. The data in Tables I-i l l  show that 
the racemic mixture produced a significant drop in 
ceramide level, possibly because of the t.-isomer. We 
plan to test this interpretation of the data bv direct 
assa,.' of ceramide svnthases in vitro. 
The speed with which the kidnevs lost glucosphin- 
golipids after treatment with CS and PDMP points to a 
rapid turnover rate for these lipids, Glucosphingolipids 
of kidne',', especially in male mice, are lost not only by 
h~'drolx'sis but also by excretion into urine 17]. It is 
possible that our observed changes might not be so 
evident in female mice or in animals (such as humans) 
in v..hich the urinary excretion of glucosphingolipids is 
somewhat slower. 
The unexpected observation that glucosphingolipids 
depletion caused an elevation in GIcCer glucosidase 
specific activity may mean that PDMP lowers gluct-,- 
sphingolipids levels not only by slowing GIcCer synthe- 
sis but also bv accelerating the normal hydrolytic loss of 
GIcCer from :,idnex'. 
The elevations in the three sphingolipid hx'drolases 
that were produced by treatment with PDMP, but not 
by CS liable V). are intriguing but the causal relation- 
ship is not obvious. Perhaps this relationship is to be 
found in the obse~'ations that: In) the hvdrolase stimu- 
lating proteins acting on GIcCer glucosidase, galacto- 
svlceramide galactosidase, and sphingomyelinase are all 
derived from a single precursor protein [27]: and that 
(b) the level of glucosidase stimulator in mice (saposin 
C) rises when the GIcCer level rises [201. The activators 
for all three enzymes accumulate in patients exhibiting 
a high level of GlcCer [27]. 
The decrease in glucuronidase that we obtained by 
decreasing GIcCer levels is mirrored by the elevation 
seen in platelets of patients with Gaucher disease [28]. 
While these changes suggest a close relation to GIcCer 
levels, our previous studies, in which the level of GIcCer 
was raised by inhibition of GIcCer glucosidase, pro- 
duced a decrease in fl-glucuronidase of cultured cells 
[221 and mouse liver and brain [14]. Perhaps the level of 
GIcCer affects only one of the intracdlular forms of this 
enzyme. 
Our discovery (Table !) that the concentration of 
CDH was lowered by Da,-PDMP is of interest as it was 
previously found, with cultured cells, that L-PDMP 
raised the CDH level considerably [3.6]. It is possible 
that the latter effect is related to the degree of cellular 
confluency and would not be seen in intact animals. A 
marked rise in CDH synthesis has been reported to 
occur as cells come into contact with one another [29]. 
While kidney was more sensitive than brain or liver 
to the side-effects of glucosphingolipids depletion, the 
changes do not seem to be great enough to produce 
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adverse effects if P D M P  were to be adminis te red  to 
pat ients  with genetic disorders  of g lucosphingol ip ids  
accumulat ion (Gaucher ,  Tay-Sachs,  Fabry ,  gangl ios ido-  
sis). Addi t ional  disorders  tb.at might  benefi t  f rom gluco- 
sphingol ipids  deplet ion are: (a) infectious diseases in 
which the pathogenic  organism is known to bind to 
glucosphingol ipids  (see Ref. 30); and (b) cancer,  in 
which glucosphingol ipids  appea r  to p lay  cri t ical  roles 
[31]. Mice treated with P D M P  for 10 days  recovered 
their growth curve quite nicely [5] and,  in the case of 
mice that  had been cured of Ehrlich ascites carc inoma,  
they were t ound to be immune to re inoculat ion with 
these cells. Thus. P D M P  t rea tment  does not  seem to 
harm the i rnmunoprotect ive system. 
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